Mrd in oncohaematology. Minimal cancer. Immune therapy of mrd.

08.50 Welcome address. Prof George Janossy, Prof Klaus Pantel, Prof Jean-Francois Rossi,

Prof Lydia Campos, Prof Bruno Brando & Dr Catherine Alix-Panabiиres

09.10 Who should be Involved in harmonizing MRD detection on solid tumours in PB and BM.Andy Rawstron,Leeds, United Kingdom

Download presentation

09.50 MRD IN ONCOHAEMATOLOGY

Chairman: Prof Lydia Campos

09.50 Prof Lydia Campos, Saint-Etienne, France. State of the art in acute myeloid leukemia minimal residual disease assessment.

Download presentation

10.10 Prof Christian Thiede, Dresden, Germany. NGS for upfront characterization and assessment of treatment response in AML and MDS.

10.30 Prof Gerrit Jan Schuurhuis, Amsterdam, The Netherlands. Minimal residual disease in AML and the role of leukemia stem cells herein.

Download presentation

10.50 Coffee break

11.20 French myeloid database: relevant tool for anticipation the most frequent recurrent genetic abnormalitie and to improve the acute myeloid leukaemia diagnostic. Dr Carmen Aanei, Saint-Etienne, France

Download presentation

11.40 MINIMAL CANCER

Chairmen:Prof Klaus Pantel & Dr Catherine Alix-Panabiиres

11.40 Circulating and disseminated tumor cells: biology and clinical significance.Prof Klaus Pantel, Hamburg, Germany

Download presentation

12.10 Methods of CTC/DTC viability and function assessment. Dr Catherine Alix-Panabiиres, Montpellier, France

Download presentation

12.40 Molecular characterization of single tumor cells by NGS. Anna Babayan, Hamburg, Germany

Download presentation

12.50 Comparative analysis of multicolor flow cytometry and immunohistochemistry for the detection of disseminated tumour cells. Eszter Szбnthу, Debrecen, Hungary

Download presentation

13.00 Selected poster presentations

13.00 Selection of DNA aptamers to human Interleukin-6 (hIL6). Vera A. Spiridonova, Moscow, Russia

13.05 Influence of c-MYC hyperexpression and RAS genes mutations on the disease prognosis and therapy response in multiple myeloma patients. M. V. Nareyko, E. Y. Demidova, A. M. Sergeeva,V. L. Surin & L. P. Mendeleeva, Moscow, Russia

13.10 Lunch

14.20 New data on DTC detection and monitoring by flow cytometry. Olga Beznos, Moscow, Russia

Download presentation

14.50 Flow Cytometry for the identification of rare cells. Sara de Biasi, Modena, Italy

15.20 IMMUNE THERAPY OF MRD

Chairmen: Prof Jean-Francois Rossi, Katherina Psarra & Prof Bruno Brando

15.20 Myeloid suppressor cells in hematological malignancies. Katherina Psarra, Athens, Greece

Download presentation

15.50 Myeloma and immune system: dangerous cross-roads. Prof Bruno Brando, Legnano, Italy

Download presentation

16.20 Coffee break

16.50 Prof Jean-Francois Rossi, Montpellier, France. New frontiers in immunopathology: from dysimmune diseases to lymphoid malignancies.

Download presentation

17.20 Targets for immune therapy of minimal residual cancer. Dr Alisa Petkevich, Moscow, Russia

Download presentation

17.30 Mechanisms of chronic myelogenous leukemia cell death induced by a new inhibitor of Bcr-Abl tyrosine kinase. Dr Ekaterina Kolotova, Moscow, Russia

Download presentation

17.40 Cancer tissue microenvironment biomarker profiling assay. Alex Chenchik, Cellecta

Download presentation

Evening with Budapest Operetta